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Introduction: A significant number of women suffer depression prior to and during pregnancy. Untreated
depression is associated with suboptimal prenatal care and often severe adverse outcomes. Selective serotonin
reuptake inhibitors (SSRIs) are commonly used antidepressants that have been inconsistently implicated in
adverse pregnancy and neonatal outcomes. The clinical question of whether a woman with perinatal
depression should choose SSRI treatment or forego it, is a common one encountered by clinicians in primary
care, and one without a satisfactory answer.
Methods: A systematic review of the past five years of English-language published literature was conducted
using MEDLINE, CINAHL, and ISI Web of Science using keywords depression, pregnancy, SSRI, and
subordinate headings. Articles of original research examining outcomes of SSRI exposure during pregnancy
were selected. Meta-analyses and case reports or series were excluded. Fifteen studies, three of which
compared SSRI exposure to untreated depression, were retrieved and analyzed for quality and significant
results.
Results: Multiple significant relationships between SSRIs and birth defects and between SSRIs and adverse
neonatal outcomes were reported, but few results were in agreement across studies, and fewer results were of
statistical or clinical significance after adjustments for known confounders were completed. Limited results
showed that SSRI exposure and untreated depression carry similar risks to mother and child.
Discussion: Current guidelines suggest individualized treatment for women with perinatal depression.
Additional prospective research efforts, perhaps even randomized placebo-controlled trials, are needed to
quantify and qualify possible risks of SSRI exposure in pregnant women. Such work should be on large
populations and should control for depression as an independent risk factor.
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Abstract   
 
Introduction: A significant number of women suffer depression prior to and during 
pregnancy. Untreated depression is associated with suboptimal prenatal care and often 
severe adverse outcomes. Selective serotonin reuptake inhibitors (SSRIs) are commonly 
used antidepressants that have been inconsistently implicated in adverse pregnancy and 
neonatal outcomes. The clinical question of whether a woman with perinatal depression 
should choose SSRI treatment or forego it, is a common one encountered by clinicians in 
primary care, and one without a satisfactory answer. 
Methods: A systematic review of the past five years of English-language published 
literature was conducted using MEDLINE, CINAHL, and ISI Web of Science using 
keywords depression, pregnancy, SSRI, and subordinate headings. Articles of original 
research examining outcomes of SSRI exposure during pregnancy were selected. Meta-
analyses and case reports or series were excluded. Fifteen studies, three of which 
compared SSRI exposure to untreated depression, were retrieved and analyzed for quality 
and significant results. 
Results: Multiple significant relationships between SSRIs and birth defects and between 
SSRIs and adverse neonatal outcomes were reported, but few results were in agreement 
across studies, and fewer results were of statistical or clinical significance after 
adjustments for known confounders were completed. Limited results showed that SSRI 
exposure and untreated depression carry similar risks to mother and child. 
Discussion: Current guidelines suggest individualized treatment for women with 
perinatal depression. Additional prospective research efforts, perhaps even randomized 
placebo-controlled trials, are needed to quantify and qualify possible risks of SSRI 
exposure in pregnant women. Such work should be on large populations and should 
control for depression as an independent risk factor. 
Keywords: depression, pregnancy, SSRI 
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INTRODUCTION 
Overview 
 
Depression is a very common condition in women, with an estimated lifetime incidence 
of 20%.1 Incidence is greatest between the ages of 20 and 40, coinciding with the typical 
childbearing years.2  While there is a belief that pregnancy may be a maternally 
protective time of emotional well-being,3 the incidence of depression in pregnancy has 
been variously reported to be between 10 and 25%,4-7 and may be vastly underreported 
due to the common feelings of  stigma and guilt that may lead pregnant women to avoid 
treatment.8 The medical literature contains many reviews that address depression and 
pregnancy.3, 9-12 
The risk factors for depression in pregnancy are many. The most significant is a prior 
history of depression.6, 13, 14  Others include younger age, living alone, limited social 
support, a history of abuse, relationship conflict, and ambivalence about the pregnancy.6, 
13, 15  About 50% of all pregnancies are unplanned,16 and many women find themselves 
unprepared for the major changes ahead of them when they learn of their pregnancy. 
Depression in pregnancy is associated with a number of adverse outcomes. It is 
postulated that depression, stress, and anxiety can activate the hypothalamic-pituitary-
adrenal (HPA) axis and other hormone systems, leading to hormonal imbalances during 
pregnancy and which can influence the timing and onset of delivery.3, 17  Depression is 
also linked to fetal abnormality, spontaneous abortion, gestational hypertension and pre-
eclampsia, neonatal intensive care unit (NICU) admissions, low birth weight, and 
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premature birth.3, 18-23 Most seriously, depression in pregnancy is associated with suicide, 
with as many as 15% of untreated women attempting suicide during pregnancy.24, 25 
As few as 13% of depressed pregnant women obtain treatment for their depression.8 
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed 
medications for depression, but only 2-3% of pregnant women are estimated to take 
them.13, 26 In fact, 50% of women who use SSRIs for depression reduce or cease using, 
either unilaterally or at the suggestion of their doctors, when discovering their 
pregnancies.27  This is likely due to a combination of the mixed evidence indicating the 
possibility of adverse effects and of the tendency to use extreme caution with pregnancy. 
This concern and associated reduction in treatment leads to a depression relapse rate of 
approximately 70% during pregnancy.27, 28 
The historical literature is replete with research on SSRIs. Fluoxetine has been the subject 
of the most extensive investigation, followed by paroxetine. The newer SSRIs, sertraline, 
citalopram, and escitalopram have been less extensively examined, but not ignored. Birth 
defects generally occur in the first trimester of gestation, and fluoxetine appears to be 
relatively safe when used in early pregnancy.29 Paroxetine was linked to cardiac 
malformations in early study, leading to voluntary warning label revision by its maker in 
2005.29-31  The newer SSRIs also appear to be safe in the first trimester.30 
A tremendous amount of research has been conducted into the use of SSRIs during the 
third trimester, with substantially varied outcomes. The majority of information available 
indicates that SSRI use late in pregnancy may be associated with adverse neonatal 
manifestations, including behavioral changes, motor symptoms, respiratory distress, 
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somatic symptoms, and gastrointestinal symptoms,26 but that these manifestations are 
mild, transient, self-limiting, and ultimately not associated with any instances of neonatal 
death.32  
So, in its crudest form, the debate between treating perinatal depression with SSRI and 
foregoing treatment can be reduced to death, or lack thereof. Some depressed women, left 
untreated, die by their own hand, while no women being treated with SSRIs were 
reported to have committed suicide in any of the literature reviewed for this work. There 
is a scarcity of literature comparing treated and untreated perinatal depression,33 and 
every study to date has been subject to methodological limitations relating to the ethics of 
experimentation on mothers-to-be.34 
Of additional concern is the likelihood that factors other than depression are responsible 
for the results of prior and future investigation. Depressed women are more likely to 
make unhealthy choices, whether antenatally, perinatally, or postnatally.35 They are more 
likely to smoke, to drink alcohol, and to abuse other substances.36 They may receive less 
prenatal care, or avoid it altogether.8 Maternal age, race, and socioeconomic status are 
additional factors independent of depression that can adversely impact pregnancy.36 
Purpose of Study 
The best research would attempt to control for all potential confounders while recruiting 
enough participants to permit statistically and clinically significant results. There is a 
dearth of historical research that accomplishes this optimum outcome. The purpose of 
this work is to systematically review the most recent clinical research regarding SSRI use 
in pregnancy, with a particular interest in studies that compare both treated and untreated 
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perinatal depression. Pregnant women must make decisions that impact both maternal 
and fetal health, and they are subject to both internal and external influences when doing 
so. Few scenarios carry the emotional weight of pregnancy. 
Clinical Question 
The question of whether a pregnant woman with depression would be better off using 
SSRIs than avoiding them is an important one, commonly encountered in primary care. 
Health care providers who consult available guidelines and literature find that no easy-to-
apply standard exists, and that risks must be weighed on an individual basis.19  Because 
of the individual nature of treatment, because of the equivocal nature of the evidence in 
the historical record, and because of the frequency with which the situation is 
encountered, it is imperative to remain abreast of new information relevant to this 
question. 
METHODS 
Search Strategy 
This systematic review examines original research that contributes to the understanding 
of the risks and benefits of SSRI use in pregnancy, particularly with regard to perinatal 
and neonatal outcomes. Only studies published in the last five years comparing SSRI 
exposure to non-exposure in pregnancy are included. Randomized controlled trials, 
cohort studies, and case-controlled studies, both prospective and retrospective, are 
included, even though retrospective studies using maternal interviews to glean data about 
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past events may be subject to recall bias. Meta-analyses and case reports are not 
addressed. 
A search of the literature published in the previous five years was conducted on the 
MEDLINE, CINAHL, and ISI World of Science databases using the following search 
terms: depression, pregnancy, SSRI. Subsidiary MeSH terms were selected where 
appropriate and permitted by the search engine (IE- “serotonin uptake inhibitors” 
secondary to “SSRI”). Subsequent examination of bibliographic entries in retrieved 
works yielded additional studies for consideration. 
Inclusions/Exclusions 
The search was then limited to English language publications and adult subjects. Studies 
with a focus on antidepressants other than SSRIs, on postpartum depression, or on 
outcomes beyond the neonatal period were excluded. After these exclusions, fifteen 
articles, of which only three purported to compare both SSRI exposure and untreated 
depression, were appraised. (see table 1). 
Using an original method (see table 2), a relative score representing quality and validity 
was assigned to each article. Higher scores were awarded for population/cohort studies, 
for prospective and controlled investigations, and for large sample populations. Lower 
scores were earned by retrospective studies, those with minimal effort to minimize 
confounding factors, and those with smaller experimental groups. No studies were 
eliminated from the review by score. Scores guide the review but do not preclude the 
consideration of good premise with poor execution.   
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RESULTS 
Birth Defects 
Some studies looked specifically at the relationship that SSRIs may have to congenital 
malformations, generally confining investigation to SSRI use in the first trimester of 
pregnancy, when most birth defects occur. Others examined SSRI use over the entire 
pregnancy and reported malformation outcomes as part of a larger picture. Nine of the 
fifteen reviewed articles contributed new knowledge about these risks. 
In a retrospective study with over 13,000 participants published in the New England 
Journal of Medicine, Alwan et al reported in 2007 that first trimester use of SSRIs, as a 
class, was not associated with any of several major birth defects, including those cardiac 
in nature. Class associations were reported for three rare defects, anencephaly (Odds 
Ratio (OR) 2.4, Confidence Interval (CI) 1.1-5.1), craniosynostosis (OR 2.5, CI 1.5-4.0), 
and omphalocele (OR 2.8, CI 1.3-5.7).  A few single drug associations were reported, but 
it is noteworthy that paroxetine was associated with only one cardiac defect, right 
ventricular outflow tract obstruction defects (OR 2.5, CI 1.0-6.0).37 
In the same issue of the New England Journal of Medicine, Louik et al found similar 
risks of first trimester paroxetine exposure for right ventricular outflow tract obstruction 
defects (OR 3.3, CI 1.3-8.8), but did not find evidence of association to anencephaly, 
craniosynostosis, or omphalocele.38 Both studies used data from the Slone Epidemiology 
Center Birth Defects Study, and had seemingly large populations (Louik et al had more 
than 15,000), but lamented that their sample sizes relatively limited the statistical power 
of their research, particularly when focusing on very rare outcomes.37, 38 
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In another study with large numbers, Swedish academics Källén and Olausson used 
national health registries to gather data on SSRI exposures and were able to establish only 
one malformation association for the class of medicines despite SSRI use in 6,481 
subjects and an overall control population greater than 860,000. Cystic kidney 
malformations were statistically significant (OR 3.50, CI 1.60-6.65), but the researchers 
noted that the number of malformations, only nine, was small and that distinctly different 
morphology present among the nine suggested five separate etiologies. Like the above 
mentioned works, the Swedish study looked specifically at paroxetine and cardiac 
malformations, and did note an association, but only when all cardiac malformations 
were considered together (OR 1.63, CI 1.05-2.53).39 
Only one other article published a positive association between SSRI and birth defects, 
and it was a study of much smaller scale that addressed birth defects only in broad terms. 
Somewhat counter to the other findings, Diav-Citrin et al showed only an association 
between fluoxetine and major malformations (OR 4.47, CI 1.31-15.27). Prior to 
considering maternal age, smoking status, and other factors, a crude association existed 
for paroxetine, but it ceased to be significant following adjustment.40 
Five articles reported no statistically significant link between SSRI and congenital 
malformation.41-45  Malm et al explored SSRIs both as a group and individually, and 
noted no differences in their matched 1782 pairs of subjects.41  In another, smaller study 
of citalopram only, Sivojelezova et al found no significant differences across groups 
when analyzing spontaneous abortion, stillbirth, and major malformation. They also 
noted no incidence of cardiac malformation in their population of 132 women exposed to 
SSRIs.43 Three other works, primarily focused on prenatal outcomes but including first 
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trimester SSRI exposure, reported with minimal detail, incidental lack of relationship 
between SSRI exposure and birth defects in their respective populations.42, 44, 45  
Late Gestation 
Some research has focused on the possible maternal effects of SSRI use in late gestation. 
If SSRI use is implicated in factors such as maternal weight gain or gestational 
hypertension, it may be a significant reason for poor pregnancy outcomes through 
indirect means. 
Wisner et al reported no significant differences in maternal weight gain among their 
multiple experimental populations when looking at both treated and untreated perinatal 
depression.45  However, in an examination of gestational hypertension and pre-eclampsia, 
Toh et al found a significant association between continuous SSRI use and the 
development of pre-eclampsia (OR 4.86, CI 2.70-8.76).46 
Gestational Age 
Gestational age and preterm delivery have been widely evaluated. While slightly 
different, the two are closely related, and an examination of average gestational age can 
yield subtle differences that would be ignored if preterm delivery were the only focus. To 
that end, both Oberlander et al (38.8 weeks vs. 39.2 weeks, p<0.001)47  and Malm et al 
(39.1 weeks vs. 39.4 weeks, p<0.001) 41  report slight but statistically significant 
differences in gestational age among their study populations. 
Perhaps of more clinical significance, several authors have described preterm delivery 
differences in their studies. Preterm infants are most commonly defined as those born 
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before thirty-seven weeks gestational age, but one article defined the threshold as thirty-
six weeks.42  Maschi et al reported significant differences at thirty-six weeks over control 
populations both for any SSRI use in pregnancy (OR 2.31, CI 1.14-4.63), and for 
continuous SSRI use (OR 4.35, CI 1.31-14.07).42  
Oberlander et al based their findings on over 100,000 subjects in a governmental register. 
They report significant differences in rates of preterm delivery when comparing SSRI use 
to untreated depression (9% vs. 6.5%, p<0.001) and when comparing untreated 
depression to women without depression (6.5% vs. 5.9%, p<0.007).47  
Wisner also compared SSRI use to untreated depression and controls, and recorded 
unadjusted significance between all groups. However, when adjusted for maternal age, 
race, and other factors, only SSRI use continued to be associated with preterm delivery 
(OR 5.43, CI 1.98-14.84). Untreated depression lost significance following adjustment 
(OR 3.71, CI 0.98-14.13).45  
One more article published findings linking SSRI use to preterm delivery and lower 
gestational age. For gestational age, Suri et al found significance in comparisons of SSRI 
use and untreated depression (38.5 weeks vs. 39.4 weeks, p<0.05), and of SSRI use and 
controls (38.5 weeks vs. 39.7 weeks, p<0.05), but not between untreated depression and 
controls. Differences in preterm delivery rates were also significant between SSRI use 
and controls (14.3% vs. 5.3%, p=0.05).48  
Conversely, two studies published contrary results about SSRIs and preterm delivery or 
gestational age. In their study of three groups of 132 subjects comparing citalopram to 
other antidepressants and controls, Sivojelezova et al identified no association in any of 
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their cohorts.43  Ferreira et al reported greater incidence of prematurity in their SSRI-
exposed group, but no statistically significant association was evident after adjustment for 
confounding variables.49  
Birth Weight 
Seven studies reported comparison results for absolute birth weight or low birth weight 
defined as below the tenth percentile,41-43, 45, 47, 48, 50 but only three studies showed any 
significant statistical relationship between SSRI use and absolute birth weight. Malm et al 
recorded a difference of ninety-nine grams between groups (p<0.001),41 Dubnov-Raz et 
al reported finding a mean difference of 230 grams (p=0.04),50  and Oberlander et al 
found thirty-two grams difference between SSRI use and untreated depression (p=0.05) 
and twenty-four grams difference between untreated depression and unexposed controls 
(p<0.001).47  No study reported significant differences among groups when examining 
birth weight below the tenth percentile. 
Other Outcomes 
Other neonatal outcomes of interest include Apgar scores, admission to special care units 
or neonatal intensive care units, persistent pulmonary hypertension of the neonate 
(PPHN), length of hospitalization, jaundice, and respiratory distress. 
PPHN Wichman et al found no relationship between SSRI use and PPHN in a 
study of 808 exposed neonates,44 but Chambers et al, in their study of 377 neonates with 
PPHN found a significant link between late pregnancy use of SSRI and PPHN (OR 6.1, 
CI 2.2-16.8).51  
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QT Prolongation In a relatively small study of 52 infants with neonatal QT 
prolongation, matched to controls, Dubnov-Raz et al recorded a nineteen millisecond 
mean difference (p<0.001) between the group exposed to SSRIs and the comparison 
group.50  The abnormalities resolved without intervention over the course of several days, 
and were reportedly of no long-term concern. 
Apgar Score Apgar scores were examined in four studies, and neither Wisner et 
al, Suri et al, nor Dubnov-Raz et al reported any statistically significant relationship 
between SSRI exposure and Apgar scores at one minute or five minutes, with or without 
adjustment for maternal age and race.45, 48, 50  Malm et al found a difference between third 
trimester exposure and earlier exposure (OR 1.6, CI 1.0-2.4) for one-minute Apgar 
score.41  
SCN/NICU Admission Several studies evaluated the possibility of a relationship 
between SSRI use and admission to a special care nursery (SCN) or a NICU. 
Sivojelezova et al found a link between third trimester exposure to citalopram and 
SCN/NICU admission (OR 4.2, CI 1.7-10.3).43  Malm et al reported similar findings, 
with third trimester SSRI exposure carrying more risk (OR 1.6, CI 1.1-2.2) than earlier 
prenatal exposure.41  Differing conclusions were made by Suri et al, Maschi et al, and 
Ferreira et al, none of whom published evidence of a link to the need for specialized 
care.42, 48, 49  
Other Neonatal Signs Jaundice, convulsions, feeding issues, central nervous 
system abnormalities, and respiratory distress were examined in several studies with 
mixed results. Wisner et al and Maschi et al found no significant relationships between 
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any of their study groups and various neonatal behavioral and adaptation signs.42, 45  
Ferreira et al found a relationship between SSRI exposure and neonatal signs as a group, 
but not individually. Nearly 78% of the exposed neonates versus 41% of the controls 
(p<0.001) presented with one or more signs (OR 3.1, CI 1.3-7.1).49  Sivojelezova et al, 
looking only at citalopram, reported a relationship between third trimester exposure and 
neonatal complications (OR 1.5, CI 1.0-2.4).43  
The study by Oberlander et al is noteworthy because of its sheer size. This permitted 
them to observe statistical, if not necessarily clinical, significance in many measures. 
They noted differences in length of hospitalization, incidence of respiratory distress, 
feeding problems, jaundice, and convulsions when comparing SSRI exposure to untreated 
depression. However, when they matched the participants by propensity score, in an 
attempt to compare women of relatively equal levels of depression, the differences in 
neonatal outcomes disappeared with the exception of the incidence of respiratory distress 
(4.4%, p=0.006).47  
DISCUSSION 
Study Limitations 
The articles included in this review reflect a variety of research methods, and their results 
are of variable quality. Attempting to study the effects of a class of medications on 
pregnant women and unborn children is limiting, and ethical considerations prevent 
randomized controlled trials in most cases. As such, prospective and retrospective 
population, cohort, or case-matched studies comprise the bulk of the available research. 
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Retrospective study can be effective, and many of the studies in this review are 
retrospective in nature. Four of them, Alwan et al, Chambers et al, Louik et al, and Toh et 
al rely on interviews with participants at as long as one year after the behaviors and 
exposures being investigated.37, 38, 46, 51  This presents a possible recollection bias 
mentioned by the authors of the articles in question. Other retrospective studies39, 47 used 
institutional databases and registries that are perhaps more reliable than personal 
recollections of subjects, but the researchers must still place reliance on data of the past 
that was recorded by complete strangers. Thus, the results of retrospective study must 
always be evaluated with some degree of skepticism. 
This topic also highlights the limitations of small studies. Events such as birth defects are 
often so rare that even studies like Alwan et al and Louik et al can reach opposing 
conclusions even though their respective studies each looked at more than ten thousand 
subjects. Smaller studies like Wisner et al, with only 238 women, hardly seem to stand a 
chance of achieving meaningful statistical significance for events as rare as birth defects 
are in absolute terms. 
Confounders 
Confounding variables are another crucial part of every one of these papers. Some 
populations simply aren’t equal. As discussed earlier, depressed women are more likely 
to smoke, to drink, and to make poor health care decisions. Nearly every research team 
attempted to control for a variety of variables, and their adjusted data commonly lost 
statistical significance in the process. This isn’t cause for lament, but merely evidence 
that this complex puzzle makes meaningful results much more difficult to achieve. 
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Bias can be introduced due to the presence of depression alone. Bar-Oz et al noted52 that 
women using antidepressants in pregnancy had a 30% higher rate of ultrasound usage 
than other women, and that this difference could be responsible for a detection bias great 
enough to result in the increases in cardiac malformation that have been noted in infants 
exposed to paroxetine in utero.52  
The impact of depression, as an independent risk factor for adverse outcome, has not 
been well investigated to date. Only three articles in this review, Wisner et al, Oberlander 
et al, and Suri et al, have made an attempt to investigate depression separately from 
depression and SSRI use,45, 47, 48  and only one other,53 from an excluded time period, was 
located during the literature search. The sheer size of the study likely helped Oberlander 
et al observe significant associations where Wisner et al and Suri et al could not, as did 
their unique attempt to match levels of depression with their propensity score system.47  
Future Avenues 
Based on the varied results of the most current research presented here, additional study 
is clearly warranted. Future researchers should follow the lead of Wisner et al and Suri et 
al, with prospective study of women with varying SSRI status, and should improve on 
their foundation by recruiting larger numbers of participants. They should do a better job 
of following the participants, of quantifying their exposures, of eliminating confounding 
variables, and of clearly documenting and presenting the results of their work. 
Future research should attempt to replicate past study as well. When a respected journal 
publishes two works with oppositional conclusions in the same issue, as the New England 
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Journal of Medicine did with Alwan et al and Louik et al, it can be assumed that the true 
conclusion is still available for discovery or confirmation.  
Considering postpartum depression in the discussion is another avenue for future 
research. Adding levels of complexity doesn’t make the work any easier, but the clinical 
scenarios faced by patients and providers are inherently complex and often more than a 
little messy. In the meantime, the prudent clinician will continue to follow available 
guidelines and treat each patient with individual consideration. 
Is it time for randomized clinical trials? At least one team believes that placebo-
controlled randomized clinical trials of SSRI in pregnant women can and should be 
performed within today’s standards of ethical research.34  Even using this systematic 
review, one could cite several examples where SSRIs were not associated with birth 
defects or with anything other than transient neonatal outcomes. 
CONCLUSION 
The question of whether or not to use SSRIs in managing perinatal depression is an 
important and practical one for the practicing health care provider. The current standard 
of care entails treating each patient as her individual circumstances warrant. Some 
evidence suggests that SSRIs increase the likelihood of birth defects and prematurity, 
both of which are significant occurrences, complicating efforts to care for mother and 
child. The picture is clouded by other evidence suggesting there is no link between SSRI 
use and adverse outcomes. The wise clinician will strive to understand, not only the 
relative risks, but also the absolute risks associated with treatment options, and by doing 
so help his or her patient navigate and manage her own health. 
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TABLE 1: Matrix of Reviewed Literature 
 
Study/Design Population Comparison Outcomes Score (of 5)/Comments 
Toh et al (2009) 
Retrospective 
Cohort 
 
5731 women 
and infants 
SSRI vs. no SSRI Gestational 
hypertension, 
pre-eclampsia 
3/5. Reporting error in abstract. 
Maternal interviews. Adjusted for 
confounding factors. 
Wichman et al 
(2009) 
Retrospective 
Cohort 
 
25214 infants SSRI vs. no SSRI CHD, VSD, PPHN 2/5. No evidence of homogeneity or 
confounding factors in maternal 
population. 
Wisner et al 
(2009) 
Prospective 
Cohort 
107 women 
131 controls 
SSRI and 
depression vs. no 
SSRI, no 
depression 
Birth defects, 
maternal weight 
gain, birth 
weight, preterm 
birth, neonatal 
outcomes 
 
4/5. Stratifies depression 
independently. Larger sample sizes 
needed for significance following 
adjustments for confounders.  
Diav-Citrin et al 
(2008) 
Prospective 
case-control 
724 women 
1467 controls 
Fluoxetine or 
paroxetine in 1st 
trimester vs. no 
SSRI 
Birth Defects, 
birth weight, 
gestational age, 
neonatal 
complications 
 
3/5. Good design, but small sample 
and lack of independent 
consideration of depression. 
Participants were self-referred. 
Dubnov-Raz et al 
(2008) 
Retrospective 
case-control 
 
52 infants 
52 controls 
SSRI in 3rd 
trimester vs. no 
SSRI 
QT prolongation 2/5. No consideration of maternal 
case matching beyond SSRI use. 
Small study. 
Ferreira et al 
(2008) 
Retrospective 
Cohort 
 
76 mothers 
and infants 
90 controls 
SSRI in 3rd 
trimester vs. no 
SSRI 
Premature birth, 
admission to 
SCN, neonatal 
outcomes 
2/5. Small study with limited 
evidence of population 
homogeneity. Twins not excluded. 
Alwan et al 
(2007) 
Retrospective 
case-control 
 
9622 infants 
with birth 
defects 
4092 controls 
SSRI in early 
pregnancy vs. no 
SSRI 
Birth Defects 3/5. Rare malformations make 
associations difficult despite large 
numbers. 
Chambers et al 
(2006) 
Retrospective 
case-control 
 
337 infants 
with PPHN 
836 controls 
SSRI in late 
pregnancy vs. no 
SSRI 
PPHN 3/5. Clear adjusted results. Larger 
numbers would improve results. 
Maschi et al 
(2008) 
Prospective 
Cohort 
200 infants 
1200 controls 
SSRI vs. no SSRI Birth defects, 
birth weight, 
gestational age, 
hospitalization, 
neonatal 
adaptation 
 
2/5. Small study with no evidence of 
adjustment for confounders. Does 
not address depression 
independently. 
Källén & 
Olaussen (2007) 
Retrospective 
Cohort 
 
860215 
women 
 
SSRI in 1st 
trimester vs. no 
SSRI 
Birth defects 3/5. Analysis of individual SSRI. Not 
reliant on maternal recollection. 
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Louik et al 
(2007) 
Retrospective 
case-control 
 
9849 infants 
with birth 
defects 
5860 controls 
SSRI in 1st 
trimester vs. no 
SSRI 
Birth defects 3/5. Reliant on maternal recall. 
Sample still small to detect rare 
events. Barely 60% participation. 
Suri et al (2007) 
Prospective 
case-control 
49 women 
41 controls (2 
groups: 22 & 
19) 
Antidepressants 
and depression 
vs. no 
medications, no 
depression 
 
Gestational age, 
birth weight, 
Apgar score, 
admission to 
SCN 
2/5. Purports to deal with depression 
independently, but data is 
confounded. Small size further 
compromised by many dropouts. 
Oberlander et al 
(2006) 
Retrospective 
Cohort 
119547 
mothers and 
infants 
SSRI and 
depression vs. no 
SSRI, no 
depression 
Birth weight, 
preterm birth, 
length of 
hospitalization, 
neonatal 
symptoms 
 
4/5. Large numbers with adjustment 
for confounders and for severity of 
depression as an independent factor. 
Malm et al 
(2005) 
Retrospective 
case-control 
1782 women 
1782 controls 
SSRI vs. no SSRI Birth defects, 
gestational age, 
birth weight, 
Apgar score, 
admission to 
SCN  
 
3/5. Adjusts for confounders and has 
moderate sample size. Difficult to 
extract information from the work. 
Sivojelezova et 
al (2005) 
Prospective 
case-control 
132 women 
264 controls 
(2 groups of 
132) 
Citalopram vs. 
non-SSRI 
antidepressants, 
no 
antidepressants 
 
Birth defects 
and perinatal 
complications 
2/5. Small study that does not 
address confounders. Limited 
explanation of process. 
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TABLE 2: Appraisal Criteria 
 
Criterion Score +1 Score 0 
Study Type Randomized controlled trials, 
Prospective cohort, 
Prospective case-controlled 
 
Retrospective, 
Case series, 
Case study 
Sample Size Total participants >1000 
 
Total participants <1000 
Confounding Factors Acknowledgement and explanation of 
confounders, 
Comparison of group attributes, 
Adjustment for confounders, 
Explanation for non-adjustment 
 
No acknowledgement of 
confounders, 
No comparison of group 
attributes 
Clearly Evident and Accurate 
Results 
Clear and accurate data sets or tables, 
Concise explanation of results in 
appropriate groupings 
 
Errors in reporting, 
Hidden information, 
Logic disconnects 
Independence of Depression Untreated depression presented as an 
independent variable, 
Depression state is considered in data 
adjustment for confounders 
 
Depression ignored as 
variable 
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